FGF21 Levels in Pheochromocytoma/Functional Paraganglioma

Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients an...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 11; no. 4; p. 485
Main Authors Klímová, Judita, Zelinka, Tomáš, Rosa, Ján, Štrauch, Branislav, Haluzíková, Denisa, Haluzík, Martin, Holaj, Robert, Krátká, Zuzana, Kvasnička, Jan, Ďurovcová, Viktorie, Matoulek, Martin, Novák, Květoslav, Michalský, David, Widimský Jr, Jiří, Petrák, Ondřej
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 05.04.2019
MDPI
Subjects
Online AccessGet full text
ISSN2072-6694
2072-6694
DOI10.3390/cancers11040485

Cover

Abstract Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.
AbstractList Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age ( = 0.005), BMI ( = 0.028), glycemia ( = 0.002), and glycated hemoglobin ( = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.
Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.
Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.
Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age ( p = 0.005), BMI ( p = 0.028), glycemia ( p = 0.002), and glycated hemoglobin ( p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.
Author Petrák, Ondřej
Rosa, Ján
Michalský, David
Widimský Jr, Jiří
Matoulek, Martin
Zelinka, Tomáš
Haluzíková, Denisa
Novák, Květoslav
Ďurovcová, Viktorie
Kvasnička, Jan
Holaj, Robert
Haluzík, Martin
Klímová, Judita
Štrauch, Branislav
Krátká, Zuzana
AuthorAffiliation 6 First Department of Surgery of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; david.michalsky@vfn.cz
3 Centre for Experimental Medicine and Diabetes Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic; martin.haluzik@ikem.cz
2 Institute of Sports Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, 120 00 Prague, Czech Republic; Denisa.Haluzikova@vfn.cz
5 Department of Urology of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; Kvetoslav.Novak@vfn.cz
1 Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; Tomas.Zelinka@vfn.cz (T.Z.); Jan.Rosa@vfn.cz (J.R.); Branislav.Strauch@vfn.cz (B.Š.); Robert.Holaj@vfn.cz (R.H.
AuthorAffiliation_xml – name: 4 Institute for Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, 128 08 Prague, Czech Republic
– name: 3 Centre for Experimental Medicine and Diabetes Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic; martin.haluzik@ikem.cz
– name: 5 Department of Urology of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; Kvetoslav.Novak@vfn.cz
– name: 6 First Department of Surgery of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; david.michalsky@vfn.cz
– name: 2 Institute of Sports Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, 120 00 Prague, Czech Republic; Denisa.Haluzikova@vfn.cz
– name: 1 Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; Tomas.Zelinka@vfn.cz (T.Z.); Jan.Rosa@vfn.cz (J.R.); Branislav.Strauch@vfn.cz (B.Š.); Robert.Holaj@vfn.cz (R.H.); Zuzana.Kratka@vfn.cz (Z.K.); Jan.Kvasnicka3@vfn.cz (J.K.); viktoria.durovcova@gmail.com (V.Ď.); martin.matoulek@vstj.cz (M.M.); Jiri.Widimsky@vfn.cz (J.W.J.); Ondrej.Petrak@vfn.cz (O.P.)
Author_xml – sequence: 1
  givenname: Judita
  orcidid: 0000-0002-0088-0277
  surname: Klímová
  fullname: Klímová, Judita
– sequence: 2
  givenname: Tomáš
  surname: Zelinka
  fullname: Zelinka, Tomáš
– sequence: 3
  givenname: Ján
  surname: Rosa
  fullname: Rosa, Ján
– sequence: 4
  givenname: Branislav
  surname: Štrauch
  fullname: Štrauch, Branislav
– sequence: 5
  givenname: Denisa
  surname: Haluzíková
  fullname: Haluzíková, Denisa
– sequence: 6
  givenname: Martin
  surname: Haluzík
  fullname: Haluzík, Martin
– sequence: 7
  givenname: Robert
  surname: Holaj
  fullname: Holaj, Robert
– sequence: 8
  givenname: Zuzana
  surname: Krátká
  fullname: Krátká, Zuzana
– sequence: 9
  givenname: Jan
  orcidid: 0000-0002-4066-7147
  surname: Kvasnička
  fullname: Kvasnička, Jan
– sequence: 10
  givenname: Viktorie
  surname: Ďurovcová
  fullname: Ďurovcová, Viktorie
– sequence: 11
  givenname: Martin
  surname: Matoulek
  fullname: Matoulek, Martin
– sequence: 12
  givenname: Květoslav
  surname: Novák
  fullname: Novák, Květoslav
– sequence: 13
  givenname: David
  surname: Michalský
  fullname: Michalský, David
– sequence: 14
  givenname: Jiří
  surname: Widimský Jr
  fullname: Widimský Jr, Jiří
– sequence: 15
  givenname: Ondřej
  orcidid: 0000-0001-8992-3562
  surname: Petrák
  fullname: Petrák, Ondřej
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30959789$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1LAzEQxYMoflTP3qTgxUttvnazcxFErAoFPeg5zKbZNrKbaLIr-N8bsYoWzGUC83vDvDcHZNsHbwk5ZvRcCKBTg97YmBijksqq2CL7nCo-KUuQ27_-e-QopWeanxBMlWqX7AkKBagK9gnMbmacjef2zbZp7Pz4YWWDWcXQBfPehw6ns8Gb3gWP7fgBIy7RL1uXG4dkp8E22aN1HZGn2fXj1e1kfn9zd3U5nxjJWT9pGmCLurYWDCqoysYCSFlADbzJLrhRApSolGLUyrpgJTZU1EiLiiLgAsWIXHzNfRnqzi6M9X3EVr9E12F81wGd_tvxbqWX4U2XBacVQB5wth4Qw-tgU687l4xtW_Q2DElzTksuOFcyo6cb6HMYYraeqUIqWeWsaaZOfm_0s8p3qhmYfgEmhpSibX4QRvXn6fTG6bKi2FAY1-Nn7NmSa__VfQAym536
CitedBy_id crossref_primary_10_1016_j_molmet_2021_101237
crossref_primary_10_3390_cancers11091391
crossref_primary_10_1097_MD_0000000000037916
Cites_doi 10.2337/db08-0392
10.1210/jc.2012-3625
10.1016/j.peptides.2007.10.007
10.2967/jnumed.106.035915
10.2337/db14-0541
10.1210/jc.2012-1132
10.1371/journal.pone.0021006
10.1210/endo-114-4-1272
10.3945/ajcn.110.001941
10.1146/annurev-nutr-071816-064800
10.1101/gad.177857.111
10.1016/j.cmet.2015.12.003
10.2337/db09-1878
10.1210/en.2010-1262
10.1016/j.molmet.2014.09.008
10.1210/en.2014-2001
10.2337/db10-0193
10.1373/clinchem.2004.045484
10.12688/f1000research.14117.1
10.1210/jc.2017-00357
10.1038/nm.3361
10.1111/j.1365-2265.2008.03502.x
10.2337/db11-0672
10.1038/nm.3249
10.2337/db07-1476
10.1210/jc.2011-2823
10.1074/jbc.M110.215889
10.1159/000107289
10.7326/0003-4819-71-2-251
10.1016/j.cmet.2017.03.005
10.1530/EJE-12-0039
10.1210/jc.2017-01257
10.1210/er.2017-00016
10.1038/ijo.2013.10
10.1111/j.1365-2265.1983.tb03184.x
10.2337/db14-0595
10.1016/j.currproblcancer.2014.01.001
10.1016/j.metabol.2013.11.014
10.1111/cen.13241
ContentType Journal Article
Copyright 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2019 by the authors. 2019
Copyright_xml – notice: 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2019 by the authors. 2019
DBID AAYXX
CITATION
NPM
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/cancers11040485
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
CrossRef
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC6520899
30959789
10_3390_cancers11040485
Genre Journal Article
GrantInformation_xml – fundername: Ministerstvo Zdravotnictví Ceské Republiky
  grantid: AZV 16-30345A
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
TUS
NPM
3V.
7T5
7TO
7XB
8FK
H94
MBDVC
PKEHL
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c421t-ff91dbbee9ca7986fe994459b92f3392c7397387710e4b516af03ba0580a9ada3
IEDL.DBID M48
ISSN 2072-6694
IngestDate Thu Aug 21 14:32:51 EDT 2025
Thu Sep 04 23:08:12 EDT 2025
Fri Jul 25 12:02:48 EDT 2025
Thu Apr 03 07:08:13 EDT 2025
Tue Jul 01 01:51:36 EDT 2025
Thu Apr 24 22:59:39 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords calorimetry
pheochromocytoma
diabetes mellitus
energy metabolism
obesity
FGF21
paraganglioma
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c421t-ff91dbbee9ca7986fe994459b92f3392c7397387710e4b516af03ba0580a9ada3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0088-0277
0000-0002-4066-7147
0000-0001-8992-3562
OpenAccessLink https://www.proquest.com/docview/2547481100?pq-origsite=%requestingapplication%&accountid=15518
PMID 30959789
PQID 2547481100
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6520899
proquest_miscellaneous_2206232274
proquest_journals_2547481100
pubmed_primary_30959789
crossref_primary_10_3390_cancers11040485
crossref_citationtrail_10_3390_cancers11040485
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20190405
PublicationDateYYYYMMDD 2019-04-05
PublicationDate_xml – month: 4
  year: 2019
  text: 20190405
  day: 5
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Cancers
PublicationTitleAlternate Cancers (Basel)
PublicationYear 2019
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References BonDurant (ref_2) 2018; 38
Liang (ref_16) 2014; 63
BonDurant (ref_33) 2016; 23
BonDurant (ref_10) 2017; 25
Bookout (ref_15) 2013; 19
Tsujimoto (ref_25) 1984; 114
Dushay (ref_32) 2015; 4
Komada (ref_38) 2017; 102
Xu (ref_18) 2009; 58
Straczkowski (ref_19) 2013; 37
Eisenhofer (ref_43) 2005; 51
Markan (ref_41) 2018; 7
Sarruf (ref_14) 2010; 59
Vienberg (ref_31) 2017; 86
Markan (ref_42) 2014; 63
Samms (ref_34) 2017; 102
Semba (ref_29) 2012; 97
Hsuchou (ref_12) 2007; 28
Zelinka (ref_24) 2009; 58
Domouzoglou (ref_3) 2011; 93
Vienberg (ref_20) 2012; 167
Lin (ref_30) 2012; 97
Colwell (ref_35) 1969; 71
Zhang (ref_28) 2008; 57
Cryer (ref_37) 1993; 17
Hadi (ref_8) 2007; 48
Rosa (ref_22) 2013; 98
Martucci (ref_17) 2014; 38
Zelinka (ref_23) 2007; 14
Snavely (ref_26) 1982; 4
Hondares (ref_5) 2011; 286
Hondares (ref_9) 2014; 63
Marek (ref_21) 2010; 59
Hale (ref_40) 2012; 153
Fisher (ref_4) 2012; 26
Matoulek (ref_27) 2009; 71
Harms (ref_6) 2013; 19
Isles (ref_36) 1983; 18
Douris (ref_11) 2015; 156
Staiger (ref_1) 2017; 38
ref_7
Tan (ref_13) 2011; 60
Fisher (ref_39) 2010; 59
References_xml – volume: 58
  start-page: 319
  year: 2009
  ident: ref_24
  article-title: The effect of pheochromocytoma treatment on subclinical inflammation and endocrine function of adipose tissue
  publication-title: Physiol. Res.
– volume: 58
  start-page: 250
  year: 2009
  ident: ref_18
  article-title: Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
  publication-title: Diabetes
  doi: 10.2337/db08-0392
– volume: 98
  start-page: 1651
  year: 2013
  ident: ref_22
  article-title: Changes in energy metabolism in pheochromocytoma
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2012-3625
– volume: 28
  start-page: 2382
  year: 2007
  ident: ref_12
  article-title: The fasting polypeptide FGF21 can enter brain from blood
  publication-title: Peptides
  doi: 10.1016/j.peptides.2007.10.007
– volume: 48
  start-page: 1077
  year: 2007
  ident: ref_8
  article-title: Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: A study of patients being evaluated for pheochromocytoma
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.106.035915
– volume: 63
  start-page: 4064
  year: 2014
  ident: ref_16
  article-title: FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting
  publication-title: Diabetes
  doi: 10.2337/db14-0541
– volume: 97
  start-page: E1224
  year: 2012
  ident: ref_30
  article-title: Dynamic change of serum FGF21 levels in response to glucose challenge in human
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2012-1132
– ident: ref_7
  doi: 10.1371/journal.pone.0021006
– volume: 114
  start-page: 1272
  year: 1984
  ident: ref_25
  article-title: Desensitization of beta-adrenergic receptors by pheochromocytoma
  publication-title: Endocrinology
  doi: 10.1210/endo-114-4-1272
– volume: 93
  start-page: 901S
  year: 2011
  ident: ref_3
  article-title: Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis
  publication-title: Am. J. Clin. Nutr.
  doi: 10.3945/ajcn.110.001941
– volume: 38
  start-page: 173
  year: 2018
  ident: ref_2
  article-title: Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis
  publication-title: Annu. Rev. Nutr.
  doi: 10.1146/annurev-nutr-071816-064800
– volume: 26
  start-page: 271
  year: 2012
  ident: ref_4
  article-title: FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis
  publication-title: Genes Dev.
  doi: 10.1101/gad.177857.111
– volume: 23
  start-page: 335
  year: 2016
  ident: ref_33
  article-title: FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2015.12.003
– volume: 59
  start-page: 1817
  year: 2010
  ident: ref_14
  article-title: Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats
  publication-title: Diabetes
  doi: 10.2337/db09-1878
– volume: 153
  start-page: 69
  year: 2012
  ident: ref_40
  article-title: Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance
  publication-title: Endocrinology
  doi: 10.1210/en.2010-1262
– volume: 4
  start-page: 51
  year: 2015
  ident: ref_32
  article-title: Fructose ingestion acutely stimulates circulating FGF21 levels in humans
  publication-title: Mol. Metab.
  doi: 10.1016/j.molmet.2014.09.008
– volume: 156
  start-page: 2470
  year: 2015
  ident: ref_11
  article-title: Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice
  publication-title: Endocrinology
  doi: 10.1210/en.2014-2001
– volume: 59
  start-page: 2781
  year: 2010
  ident: ref_39
  article-title: Obesity is a fibroblast growth factor 21 (FGF21)-resistant state
  publication-title: Diabetes
  doi: 10.2337/db10-0193
– volume: 51
  start-page: 735
  year: 2005
  ident: ref_43
  article-title: Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines
  publication-title: Clin. Chem.
  doi: 10.1373/clinchem.2004.045484
– volume: 7
  start-page: 289
  year: 2018
  ident: ref_41
  article-title: Defining “FGF21 Resistance” during obesity: Controversy, criteria and unresolved questions
  publication-title: F1000Res
  doi: 10.12688/f1000research.14117.1
– volume: 102
  start-page: 3400
  year: 2017
  ident: ref_38
  article-title: Insulin Secretion and Insulin Sensitivity Before and After Surgical Treatment of Pheochromocytoma or Paraganglioma
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2017-00357
– volume: 19
  start-page: 1252
  year: 2013
  ident: ref_6
  article-title: Brown and beige fat: Development, function and therapeutic potential
  publication-title: Nat. Med.
  doi: 10.1038/nm.3361
– volume: 17
  start-page: S43
  year: 1993
  ident: ref_37
  article-title: Adrenaline: A physiological metabolic regulatory hormone in humans?
  publication-title: Int. J. Obes Relat Metab Disord
– volume: 71
  start-page: 369
  year: 2009
  ident: ref_27
  article-title: Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity
  publication-title: Clin. Endocrinol.
  doi: 10.1111/j.1365-2265.2008.03502.x
– volume: 60
  start-page: 2758
  year: 2011
  ident: ref_13
  article-title: Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: Relationship with plasma FGF21 and body adiposity
  publication-title: Diabetes
  doi: 10.2337/db11-0672
– volume: 19
  start-page: 1147
  year: 2013
  ident: ref_15
  article-title: FGF21 regulates metabolism and circadian behavior by acting on the nervous system
  publication-title: Nat. Med.
  doi: 10.1038/nm.3249
– volume: 57
  start-page: 1246
  year: 2008
  ident: ref_28
  article-title: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
  publication-title: Diabetes
  doi: 10.2337/db07-1476
– volume: 97
  start-page: 1375
  year: 2012
  ident: ref_29
  article-title: Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: The Baltimore Longitudinal Study of Aging
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2011-2823
– volume: 286
  start-page: 12983
  year: 2011
  ident: ref_5
  article-title: Thermogenic activation induces FGF21 expression and release in brown adipose tissue
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M110.215889
– volume: 14
  start-page: 57
  year: 2007
  ident: ref_23
  article-title: Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension
  publication-title: Neuroimmunomodulation
  doi: 10.1159/000107289
– volume: 71
  start-page: 251
  year: 1969
  ident: ref_35
  article-title: Inhibition of insulin secretion by catecholamines in pheochromocytoma
  publication-title: Ann. Intern. Med.
  doi: 10.7326/0003-4819-71-2-251
– volume: 25
  start-page: 935
  year: 2017
  ident: ref_10
  article-title: FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2017.03.005
– volume: 4
  start-page: 829
  year: 1982
  ident: ref_26
  article-title: Adrenergic receptors in human and experimental pheochromocytoma
  publication-title: Clin. Exp. Hypertens. A
– volume: 167
  start-page: 49
  year: 2012
  ident: ref_20
  article-title: Impact of short-term high-fat feeding and insulin-stimulated FGF21 levels in subjects with low birth weight and controls
  publication-title: Eur. J. Endocrinol.
  doi: 10.1530/EJE-12-0039
– volume: 102
  start-page: 3806
  year: 2017
  ident: ref_34
  article-title: FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2017-01257
– volume: 38
  start-page: 468
  year: 2017
  ident: ref_1
  article-title: Fibroblast Growth Factor 21-Metabolic Role in Mice and Men
  publication-title: Endocr. Rev.
  doi: 10.1210/er.2017-00016
– volume: 37
  start-page: 1386
  year: 2013
  ident: ref_19
  article-title: Serum fibroblast growth factor 21 in human obesity: Regulation by insulin infusion and relationship with glucose and lipid oxidation
  publication-title: Int. J. Obes. (Lond)
  doi: 10.1038/ijo.2013.10
– volume: 59
  start-page: 415
  year: 2010
  ident: ref_21
  article-title: Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing’s syndrome
  publication-title: Physiol. Res.
– volume: 18
  start-page: 37
  year: 1983
  ident: ref_36
  article-title: Phaeochromocytoma and diabetes mellitus: Further evidence that alpha 2 receptors inhibit insulin release in man
  publication-title: Clin. Endocrinol.
  doi: 10.1111/j.1365-2265.1983.tb03184.x
– volume: 63
  start-page: 4057
  year: 2014
  ident: ref_42
  article-title: Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding
  publication-title: Diabetes
  doi: 10.2337/db14-0595
– volume: 38
  start-page: 7
  year: 2014
  ident: ref_17
  article-title: Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment
  publication-title: Curr. Probl. Cancer
  doi: 10.1016/j.currproblcancer.2014.01.001
– volume: 63
  start-page: 312
  year: 2014
  ident: ref_9
  article-title: Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2013.11.014
– volume: 86
  start-page: 156
  year: 2017
  ident: ref_31
  article-title: Increased glucose-stimulated FGF21 response to oral glucose in obese nondiabetic subjects after Roux-en-Y gastric bypass
  publication-title: Clin. Endocrinol.
  doi: 10.1111/cen.13241
SSID ssj0000331767
Score 2.1715324
Snippet Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21,...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 485
SubjectTerms Adrenergic receptors
Blood glucose
Blood pressure
Body fat
Body mass index
Calorimetry
Catecholamines
Diabetes
Diabetes mellitus
Energy
Energy metabolism
Fibroblast growth factors
Gene expression
Genotype & phenotype
Glucose
Glucose metabolism
Hemoglobin
Hyperglycemia
Hypertension
Insulin
Liver
Metabolic syndrome
Nervous system
Paraganglioma
Pheochromocytoma
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB7BIiEuCNoC4aUgceglbOLYiX1AqEWkqILVqioSt8hxHHYlSGB3OfDvmdk86ILoJRfbecw4nvc3AMdZGGhmIuHJPMs8QgDztPRzzyqqpMyjMGZUnHw9iC5v-O9bcbsEg7YWhtIq2zNxflDnlSEfeR8NmZhLAjg7e3zyqGsURVfbFhq6aa2Qn84hxpZhBY9k4fdg5efFYPin87r4IcrLKK4xfkK09_uGiDuZ4o05bmaxKJ4-6JzvUyf_kUXJBqw3SqT7o-b6JizZ8gusXjdh8q-gkl8JC9wrSgiauuPSHY5sZUaUeWdeZtWD7icozmovoDvUE32nqZoXB77BTXLx9_zSa3okeIazYOYVhQqQytYqo2Mlo8IqxblQmWIFfh8zMSocoYxRkbA8E0GkCz_MtC-kr5XOdbgFvbIq7Q64PJcFtxEh1uScIWcDo3FxxtD4xot04KQlTWoaAHHqY3GfoiFBtEzf0dKB792Cxxo74_Op-y2t0-YnmqZvLHfgqBvG7U8xDV3a6hnnMB8VOIa2tQPbNWu6Z4Xk44ylciBeYFo3gaC1F0fK8WgOsR0JRvHQ3f-_1h6sof40Dy75Yh96s8mzPUAdZZYdNhvvFbRh6E8
  priority: 102
  providerName: ProQuest
Title FGF21 Levels in Pheochromocytoma/Functional Paraganglioma
URI https://www.ncbi.nlm.nih.gov/pubmed/30959789
https://www.proquest.com/docview/2547481100
https://www.proquest.com/docview/2206232274
https://pubmed.ncbi.nlm.nih.gov/PMC6520899
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LS8NAEB60gngR38ZHieDBSzTZbDbZg4iKUUSliIXewmazsQVNta1g_70zSVrfl1z2ETKzm_lmZ_YbgP3U9xTTInCiLE0dYgBzVORmjpF0kzITfsjocvLtnbhq8-tO0PksB1QLcPina0f1pNqDp8P31_EJbvhj8jjRZT_SJJ_BEA0Zx_UYzMJcGSyiPL4a65e_ZR9NZVlRlrkhc4SQvKL6-WuOBZj36YQspPLvXw3WLxT6M5nyi3WKl2CxhpX2abUOlmHGFCswf1sHzldBxpcx8-wbShEa2r3CbnVNX3cpF0-PR_1ndRSjgavOBe2WGqhHRfd7sWEN2vHFw_mVU1dNcDRn3sjJc-mh3I2RWoUyErmRkvNAppLl-KlMhwhB_ChEaGF4GnhC5a6fKjeIXCVVpvx1aBT9wmyCzbMo50YQh03GGera0woHpwzdcXxEFhxORJPomlKcKls8JehakFiTH2K14GA64KVi0_i_685E1slkVSTozYY8IpY7C_amzbghKMqhCtN_wz7MRUjH0Nu2YKNSzfRdE51aEH5T2rQDkW1_byl63ZJ0WwSMIqRb_865DQsIpspIkxvsQGM0eDO7CFhGaRPmzi7uWvdNmL3seM1yWX4AYXrqCQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dT9RAEJ_AkQgvRBSlClgTTXyp12637e4DMYDUQ-4uFwIJb3W73XIk2MLdEcM_59_mzPVDD6NvvPRlP9rOzu587fwG4F3qe4rpMHBElqYOIYA5SriZYyRlUmahHzFKTh4Mw945_3oRXCzBzyYXhq5VNmfi_KDOSk0-8i4aMhEXBHD26ebWoapRFF1tSmiourRCtjeHGKsTO07M_Q804aZ7x59xvd8zFh-dHfacusqAoznzZk6eSw-_0xipVSRFmBspOQ9kKlnuo_agIxTZvohQFBueBl6octdPlRsIV0mVKR_nXYYVTg6UDqwcHA1Hp62Xx_VRPodRhSmEs7ldTYs5meKPcNw8waI4_EvHfXhV8w_ZFz-F9VpptfcrLtuAJVM8gyeDOiz_HGT8JWae3acLSFP7qrBHY1PqMd300_ez8rvqxig-K6-jPVITdakoexgbNuH8Uaj1AjpFWZgtsHkmcm5CQsjJOENO8rTCwSlDYx8fwoKPDWkSXQOWU92M6wQNF6Jl8oCWFnxoB9xUWB3_7rrd0DqpN-00-c1iFrxtm3G7UQxFFaa8wz7MRYWRoS1vwctqadp3-eRTjYS0IFpYtLYDQXkvthRX4zmkdxgwir---v9nvYHV3tmgn_SPhyevYQ11t3lgyw22oTOb3Jkd1I9m6W7NhDZ8e2y-_wUHdCU9
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB7xkBAX1DehlKZSK_WSbuI4iX1AVQsEKLBaVUXiFhzHYVeCBHYXVfzF_qrObJy0C2pvXHLxI8l47JnxzHwD8D4PA8V0HHmiyHOPEMA8JfzCM5IyKYs4TBglJ5_044NT_u0sOluAX20uDIVVtmfi7KAuak135D00ZBIuCOCsV9qwiMFu-vn6xqMKUuRpbctpKFtmodiewY3ZJI8jc_cTzbnJ9uEurv0HxtK9HzsHnq044GnOgqlXljLAbzZGapVIEZdGSs4jmUtWhqhJ6ATFdygSFMuG51EQq9IPc-VHwldSFSrEeRdhGXtJNASXv-71B9-7Gx8_RFkdJw2-EM7m9zQt7HiCP8VxI0XzovGBvns_bPMvOZg-gTWrwLpfGo57CgumegYrJ9ZF_xxkup-ywD2mYKSJO6rcwdDUekhRf_puWl-pXoqitLmBdAdqrC4UZRJjwws4fRRqvYSlqq7MOri8ECU3MaHlFJwhVwVa4eCcoeGPD-HAp5Y0mbbg5VRD4zJDI4Zomd2jpQMfuwHXDW7Hv7tutrTO7AaeZH_YzYF3XTNuPfKnqMrUt9iH-ag8MrTrHXjVLE33rpDuVxMhHUjmFq3rQLDe8y3VaDiD944jRr7Yjf9_1ltYQf7Pjg_7R69hFdW4mY_LjzZhaTq-NW9QVZrmW5YHXTh_bLb_DZKjKYE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FGF21+Levels+in+Pheochromocytoma%2FFunctional+Paraganglioma&rft.jtitle=Cancers&rft.au=Kl%C3%ADmov%C3%A1%2C+Judita&rft.au=Zelinka%2C+Tom%C3%A1%C5%A1&rft.au=Rosa%2C+J%C3%A1n&rft.au=%C5%A0trauch%2C+Branislav&rft.date=2019-04-05&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=11&rft.issue=4&rft_id=info:doi/10.3390%2Fcancers11040485&rft_id=info%3Apmid%2F30959789&rft.externalDocID=30959789
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon